Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands

Mangen, M.; Rozenbaum, M.; Huijts, S.; H. Van Werkhoven, C.; Postma, D.; Atwood, M.; V. van Deursen, A.; van der Ende, A.; Grobbee, D.; Sanders, E.; Sato, R.; Verheij, T.; E. Vissink, C.; Bonten, M.; de Wit, G.

doi:10.1183/13993003.00325-2015

Public

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands

Published in The European Respiratory Journal • Jul 9, 2015

Authors:

M. Mangen

M. Rozenbaum

S. Huijts

Abstract

The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-type community-acquired pneumonia and vaccine-type invasive pneumococcal disease in elderly subjects. We examined the cost-effect...

View

Open Access

Subject

Medicine

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!